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ABSTRACT
Genetic alterations involving TMPRSS2-ERG alterations and deletion of key tumor 
suppressor genes are associated with development and progression of prostate cancer 
(PCa). However, less defined are early events that may contribute to the development 
of high-risk metastatic prostate cancer. Bioinformatic analysis of existing tumor 
genomic data from PCa patients revealed that WAVE complex gene alterations 
are associated with a greater likelihood of prostate cancer recurrence. Further 
analysis of primary vs. castration resistant prostate cancer indicate that disruption 
of WAVE complex gene expression, and particularly WAVE1 gene (WASF1) loss, is 
also associated with castration resistance, where WASF1 is frequently co-deleted 
with PTEN and resists androgen deprivation therapy (ADT). Hence, we propose that 
WASF1 status defines a subtype of ADT-resistant patients. Better understanding of 
the effects of WAVE pathway disruption will lead to development of better diagnostic 
and treatment modalities.
INTRODUCTION
As the most-common noncutaneous cancer in men 
worldwide [1], mechanisms contributing to development 
of prostate cancer at all stages of disease remain of high 
interest for both diagnosis and treatment of clinically-
relevant disease. Consistent with the multi-hit hypothesis, 
several genes that control critical growth, survival, and/
or apoptotic pathways [2] must be altered to lead to fully 
penetrant prostate cancer [3–5]. A wide body of literature 
has identified many complex genetic alterations involved 
in neoplastic transformation, including TMPRSS2-ETS 
(ERG) chromosomal translocations and deletion of tumor 
suppressor genes (PTEN, TP53, RB1, NKX3–1, and 
CDKN1B) [3–10]. Of these, selection for the deletion 
of PTEN (phosphatase and tensin homolog) occurs in 
approximately 30% of prostate cancers, as lowered 
levels of PTEN increase the availability of phosphatidyl-
inositol 3, 4, 5 triphosphate (PIP3) for driving PI 3-kinase 
(PI3K)-dependent signaling, such as cellular growth 
pathways downstream of AKT (protein kinase B) [7, 11]. 
In addition, we previously implicated ABI1 (SSH3BP1) as 
a putative tumor suppressor in prostate cancer [12] and 
have demonstrated that disruption of Abi1 in the mouse 
prostate leads to prostatic intraepithelial neoplasia (PIN), 
but not to invasive prostate cancer [13]. We have therefore 
sought to find additional genes that cooperate with ABI1 in 
prostate tumor progression.
In cells Abi1 is incorporated in the WAVE complex. 
In mammalian cells, several distinct WAVE complexes can 
form, depending on the isoform of proteins that is expressed 
[14]. Each WAVE complex assembles from ubiquitously 
expressed variants of 5 polypeptides: WAVE, Abelson inter­
actor (Abi or SSH3BP1), Rac1-associated protein (Sra-1), 
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Nck-associated protein (Nap), and Brk1 (HSPC300) 
[15–17]. Except for Brk1 [18], for which only one isoform 
exists, each of these proteins is a member of a protein family 
consisting of 2–3 genes in mammals including alternatively 
spliced isoforms of 10 genes [14, 19]: (i) WASF1, WAVE2 
(WASF2), and WAVE3 (WASF3), (ii) ABI1, ABI2, and 
ABI3, (iii) Sra-1 and PIR121 (CYFIP1 and CYFIP2), and 
(iv) Nap1 (NCKAP1) and Hem1 (NCKAP1L1). Functionally, 
WAVE complexes are major actin cytoskeleton regulatory 
factors that promote actin polymerization through an Arp2/3 
dependent mechanism [20]. Other functions of WAVE 
complex or its components involve binding to variety of 
membrane receptors [21], intracellular signaling [22, 23], 
and transcription [22, 24]. WAVE complexes are involved 
in cell motility and migration, cellular adhesion, cell-to-cell 
communication, cell division, and immunological responses 
[17, 25–31]. Thus, WAVE complexes are involved numerous 
cellular functions requiring actin cytoskeleton reorganization 
and dynamics, processes with roles in tumor progression and 
metastasis [32].
Consistent with this, dysregulation of WAVE 
complex or its components is associated with human 
cancer [33–35] including prostate cancer [12, 36–39], as 
the WAVE pathway cross talks with the PI3K pathway. It 
has been shown previously that PIP3 can bind directly to 
WAVE protein [40], and we and others have demonstrated 
that the p85 regulatory subunit of PI3K interacts with Abi1 
[23, 41]. Importantly, we have also shown that genetic 
inactivation of Abi1 led to down-regulation of WASF1 
(and WASF2 [42]) which in turn resulted in increased 
phosphorylation of Akt in murine prostate tissue [13]. 
To this effect, altered levels of WAVE complex genes 
would result in disruption of the WAVE complex’s ability 
to regulate p85, and thus would phenocopy deletion of 
PTEN in mediating cancer progression. Therefore we 
hypothesize that prostate cancers select for cells with 
lower levels of WAVE complex proteins.
In patients with metastatic PCa, standard treatments 
involve either surgical or medical castration, which 
effectively prevents testicular testosterone from driving 
androgen receptor (AR) activation in the tumor cell [43]. 
The fact that most patients invariably relapse has led to 
profound interest in identifying mechanisms contributing 
to the development of castration-resistant prostate cancer 
(CRPC) and commercial production of inhibitors of adrenal 
sources of androgens and AR pathway inhibitors such 
as galeterone, abiraterone and enzalutamide [44–46]. 
However, the fact that PTEN is deleted or down-regulated 
in these cancers has intensified investigation of how 
PI3K contributes to androgen independence via a PTEN-
dependent mechanism. Not surprisingly, simultaneous 
inhibition of both AR and PI3K effectively blocked growth 
of human PCa xenografts [47–49]. These data further 
reinforce the need to identify causative mechanisms of 
CRPC development, especially in the context of PTEN 
deletion.
Therefore, to assess whether prostate cancer 
progression to castration resistance is mediated by changes 
to WAVE complex, we performed bioinformatic meta­
analyses on several published datasets, including mutation, 
copy number, and gene expression data accumulated 
as part of The Cancer Genome Atlas (TCGA), as well 
as other publicly-available datasets deposited in GEO 
from experiments performed at Beth Israel Deaconess 
Medical Center (BIDMC), Memorial Sloan Kettering 
Medical Center (MSKCC) and the University of Michigan 
(UMICH) [7, 10, 50]. By comparing results across 
independent cohorts, we observed shifts in the frequency 
of WAVE complex gene alterations, which suggest that 
WAVE complex disruption may be a putative driver of 
prostate tumorigenesis. Importantly, we observed that 
deletion of WASF1, the gene that codes for WAVE1, 
occurs more frequently with PTEN deletion in metastatic 
lethal vs. primary disease, suggesting that WASF1 loss 
represents an aggressive of subtype of prostate cancer. It is 
thus possible that patients who harbor tumors with WASF1 
deletion may benefit from either earlier or more aggressive 
intervention.
RESULTS AND DISCUSSION
We had previously assessed the status of ABI1 
in a small cohort of primary prostate tissue [51], so we 
expanded our interrogation of WAVE complex alterations 
to The Cancer Genome Atlas (TCGA) and molecular 
analyses performed on these samples. We hypothesized 
that alterations to the WAVE complex may contribute to 
increased tumorigenicity and therefore poorer long-term 
outcome. When we interrogated the dataset for cases 
with mutations, copy number alterations, or abnormal 
expression, we found that alterations to WAVE complex 
genes were significantly associated with a 13.43% increase 
in the rate of biochemical recurrence (BCR) within 
5 years (Figure 1a). Interrogating other datasets for which 
biochemical recurrence rates were available, we observed 
a similar trend in the MKSCC dataset, where alterations 
to WAVE complex genes were associated with a 11.14% 
increase in the five­year BCR rate (Supplementary 
Figure 1). Strikingly, the most common alterations were 
not mutations (Figure 1b) nor recurrent up- or down-
regulation (Figure 1c), but rather copy number variation 
to WAVE complex genes, preeminently WAVE1 (WASF1) 
(Figure 1d), which was deleted hemizygously in 54 cases 
(16.9%) and homozygously in 32 cases (10%).
These observations are consistent with several recent 
reports that describe many recurrent translocations and 
deletions in prostate cancer and surprisingly few recurrent 
mutations. Indeed, mutations to SPOP, MED12 and FOXA1 
comprise less than 10% (each) recurrence in primary 
PCa exomes sequenced as part of TCGA and previous 
studies [52], but large chromosomal events occur far more 
frequently, with translocations (or interstitial deletions) 
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involving TMPRSS2 and ETS-family transcription factors 
(such as ERG) in approximately 50% of cases, or tumor 
suppressor deletions (PTEN, NKX3–1) in approximately 
30–50% of cases [7]. Our observation of WASF1 deletion 
was not as frequent (approximately 25%). Although these 
deletions were identified, these same cases did not indicate 
lower levels of WASF1 mRNA. While we cannot rule out 
the possibility that cells can compensate by up-regulating 
the remaining copy, recent evidence suggests that the WAVE 
complex is regulated mostly at the protein level [42, 53].
Nonetheless, the increased frequency of biochemical 
recurrence of tumors with WAVE complex gene alterations 
and our observation of recurrent deletion of WASF1 in 
primary prostate cancer therefore led us to ask whether 
WAVE complex was similarly disrupted in advanced PCa, 
in a castration­resistant (CRPC) setting. Examination 
of gene expression microarrays from 131 primary PCa 
(MSKCC dataset [7]) and 33 CRPC (BIDMC dataset 
[50]) revealed marked down-regulation of ABI1, ABI2, 
and NCKAP1 in the CRPC samples (Figure 2a). WASF1 
expression displayed modest variation (within and 
between sets), which is consistent with the observation 
from TCGA (see Figure 1c) that WASF1 down-regulation 
by itself is not a mechanism of progression in PCa, 
although down-regulation of ABI1, ABI2, or NCKAP1 may 
lead to destabilization of WAVE complex and thus lower 
levels of WAVE1 protein.
Importantly, the WAVE complex acts as a mediator 
PI-3 kinase-directed cell motility, and thus may also 
contribute to overall tumorigenenicity when dysregulated 
[54, 55]. Given its function downstream of PI3K, we 
therefore sought to explore WASF1 copy number status in 
the context of PTEN deletion, a frequent genomic lesion 
found in primary and advanced PCa [56–58]. To make 
comparisons, we selected two published datasets (from 
MSKCC [7] and UMICH [10]) in which copy number 
analysis was performed simultaneously in both primary 
PCa and CRPC. As anticipated, PTEN and WASF1 were 
frequently deleted (hemizygously and homozygously) in 
primary PCa from both datasets (Figures 2b and 2c). To 
our surprise however, PTEN and WASF1 deletion were 
mutually exclusive in primary PCa, but hemizygous 
WASF1 deletion co-occurred with both hemizygous and 
homozygous PTEN deletion in CRPC (P < 0.0001 for the 
MSKCC set, P = 0.0006, for the UMICH set). As PTEN 
and WASF1 are on different chromosomes (10q23 and 
6q21) these events are not physically linked, and because 
in CPRC nearly all WASF1 deletions were in cases that 
Figure 1: Spectrum of alterations of WAVE complex in primary prostate cancer. Data on prostate adenocarcinoma 
analyses performed as part of The Cancer Genome Atlas (TCGA) as of the time of writing was downloaded from cBioPortal [64], the 
NCBI TCGA data portal (https://tcga­data.nci.nih.gov) and CGHub [65]. a. Kaplan-Meier survival distribution showing the time until 
biochemical recurrence for patients with alterations in WAVE complex genes (ABI1, ABI2, ABI3, BRK1, CYFIP1, CYFIP2, NCKAP1, 
NCKAP1L, WASF1, WASF2, and WASF3). Log rank P value: 0.020 suggesting a significant difference between groups. b. Distribution 
of nonsynonymous somatic mutations to WAVE complex genes from 493 cases of PCa whole exome sequencing data generated by the 
TCGA. Blue: splice­site mutation; red: missense mutation; gray: unchanged. c. Gene expression changes in tumor samples relative to 
the mean of the sample set’s 75th percentile-normalized RSEM values (z-score/standard deviations, s.d.) from 493 cases of TCGA PCa 
RNA­seq data [66]. Normalized RSEM values are given in Supplementary Table 1, and z-score values are given in Supplementary Table 
2. Blue: ≥ 2 s.d. down­regulated; Red: ≥ 2 s.d. up­regulated. Note that due to variability in the purity of the tumor sample (Supplementary 
Table 3) as determined by ESTIMATE [67], some up­ or down­regulation of WAVE complex genes may be due to stromal contamination.  
d. Somatic copy number analysis of WAVE complex genes from 319 cases of TCGA PCa Affymetrix 6.0 SNP arrays, where 1 (white) = two 
copies. Red: > 1.2, inferring amplification; Blue: < 0.8, inferring deletion. Homozygous deletion: copy number less than 0.6. Hemizygous 
deletion: copy number 0.6–0.8. Cases with tumor cell purity less than 90% are excluded from totals, but values for all cases are given in 
Supplementary Table 4.
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Figure 2: WAVE complex disruption in castration-resistant prostate cancer. a. Heatmap of gene expression changes in WAVE 
complex genes relative to the mean of the sample. Microarray data for primary PCa (Affymetrix Human Exon 1.0 array, accession ID 
GSE21034) and CRPC (Affymetrix U133A array, accession ID GSE32269) were downloaded from the Gene Expression Omnibus (GEO) 
and normalized to the same scale using SCAN for Bioconductor [68]. Gene expression values in each row are displayed according to their 
z-score (number of standard deviations (s.d.) greater or lower than the mean for the sample set). Note that probes to BRK1 and ABI3 were 
not present on the Affymetrix U133A microarray and thus are excluded from this analysis. Red: high expression (greater than 1 s.d. up­
regulated); blue: low expression (greater than 1 s.d. downregulated). Normalized intensity values are given in Supplementary Table 5 and 
z-scores are values are given in Supplementary Table 6. b. Somatic copy number depiction of PTEN and WASF1 of 157 primary PCa and 
28 CRPC from the MKSCC dataset [7] (Agilent 244A aCGH array, accession ID GSE21032). P < 0.0001 by Fisher’s exact test for the 
frequency of co­occurrence of hemizygous WASF1 deletion with combined frequencies of hemizygous and homozygous deletion of PTEN 
in CRPC vs. primary PCa. Numeric copy number calls are given in Supplementary Table 7. c. Somatic copy number depiction of PTEN 
and WASF1 of 59 primary PCa and 35 lethal CRPC from the UMICH dataset [10] (Agilent 44K aCGH array, accession ID GSE35988). P = 
0.0006 by Fisher’s exact test for the frequency of co­occurrence of hemizygous WASF1 deletion with combined frequencies of hemizygous 
and homozygous deletion of PTEN in CRPC vs. primary PCa. Numeric copy number calls are given in Supplementary Table 8. For (b) and 
(c) data were downloaded from GEO and loci copy number were assessed with Nexus Copy Number software (Biodiscovery, Hawthorne, 
CA); dark blue: homozygous deletion; green: hemizygous deletion; red: amplification; gray: unchanged.
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also harbored at least one copy of PTEN (but not vice 
versa), these data suggest that WASF1 deletion is an earlier 
event preceding tumor cells’ acquisition of PTEN deletions 
that likely occur later as tumors progress.
Importantly, as PTEN and WASF1 were rarely 
deleted simultaneously in the same case in primary 
PCa (see Figures 2b and 2c), selection for dual loss 
may be associated with processes that mediate disease 
progression. Specifically, the frequency of WASF1 deletion 
in lethal prostate cancer and its co-deletion with PTEN 
raised the possibility that advanced PCa cells select for 
PTEN deletion in cases with WASF1 already deleted in 
order to drive PI 3-kinase signaling in castration-resistant 
cases with stronger AR reactivation. Furthermore, 
because we did not observe frequent homozygous 
deletion of WASF1, tumors with lower WAVE1 levels 
Figure 3: WASF1 deletion may identify an aggressive subtype of prostate cancer. a. Of the 36 CRPC samples in the BIDMC 
dataset (Affymetrix U133A array, accession ID GSE32269), the 9 samples with the highest quartile of WASF1 expression (gray, mean = 
2.67) were compared against the 9 samples with the lowest quartile of WASF1 expression (yellow, mean = 1.41), and the genes contributing 
most to the distinguishing of these groups were identified with the ComparativeMarkerSelection [69] module in GenePattern [70] (fold­
change ≥ ± 2.4 × , P < 0.05 by Student’s t­test). Red: high expression; blue: low expression. Expression intensity values are given in 
Supplementary Table 9. b. Enrichment plot of WASF1-high vs. WASF1­low gene expression and correlation with Androgen Receptor (AR) 
activity. Normalized enrichment score: –1.50; P = 0.038. c. Heatmap of gene expression associated with AR activity positively correlated 
with the WASF1­low group. Red: high expression; blue: low expression. Expression intensity values are given in Supplementary Table 10.
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(rather than total loss of WAVE1) may similarly confer 
a selective advantage at later stages of disease. Indeed, 
WASF1 expression within the BIDMC dataset of CRPC 
was varied to permit stratification of samples by the top 
quartile of WASF1 expression (WASF1-high) vs. the lower 
quartile (WASF1-low) to predict the potential effects of 
WASF1 genomic deletion (Figure 3a). Consistent with 
our hypothesis that low WASF1 expression represents 
an aggressive phenotype, we observed significant down­
regulation of the putative tumor suppressors CHD1 and 
CDH10 (cadherin-10) [59, 60]. Moreover, amongst the 
genes most up-regulated in the WASF1-low group are 
HSD17B4, which codes for an androgen inactivating 
enzyme [61], and PIP (prolactin-induced protein), 
whose expression was recently reported as a readout of 
AR (Androgen Receptor) activity [62]. Therefore, to test 
whether AR activity is indeed increased in the WASF1-
low cases, we performed Geneset Enrichment Analysis 
(high vs. low) using the expression values for all genes. 
In the WASF1-low phenotype, we observed negative 
enrichment for up-regulated genes derived from a dataset 
in which LNCaP cells were treated with methyltrienolone/
R1881 (Figure 3b) [63]. Indeed, these genes include the 
AR targets KLK3 (PSA), TMPRSS2, and FKBP5, which 
are up-regulated in the WASF1-low group (Figure 3c), 
suggesting that CRPC with lower levels of WASF1 have 
increased tumorigenicity.
While metastatic CRPC circumvents androgen 
deprivation by intratumoral testosterone synthesis 
[50], increased expression of AR target genes suggests 
higher stability of ligand-bound AR and thus higher 
levels of androgen synthesis. Because the reactivation 
of AR activity and down-regulation of additional tumor 
suppressors in these cases (see Figure 3a) represents an 
aggressive prostate cancer phenotype, deletion of WASF1 
and lower levels of ABI1 and ABI2 likely cooperate 
with other perturbations in these CRPC for overcoming 
androgen deprivation, providing a selective advantage 
for those tumors harboring these genetic changes. Thus, 
the normal function of the WAVE complex may be to 
serve as a tumor suppressor. Therefore, WASF1 deletion 
co-occurring with PTEN in advanced prostate cancers 
may result in even stronger PI3K signaling, having 
removed inhibitory forces from p85 (WASF1 deletion) 
and increasing levels of PIP3 (PTEN deletion). Further 
investigation is needed to determine the biological 
consequences of WASF1 deletion, the interactions between 
WAVE pathway and the AR signaling axis, and the role 
of WAVE pathway in establishing tumors with long-term 
aggressive potential.
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